




## Letrozole

Revised: June 21, 2021.

CASRN: 112809-51-5



## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the use of letrozole during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during letrozole therapy and for 3 weeks after the last dose.

### Drug Levels

*Maternal Levels.* An abstract reported that a relative infant dose of 10.2% was found in nursing mother(s) taking letrozole, who provided 8 milk samples over 24 hours, but other details were not supplied.[1]

*Infant Levels.* Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## References

1. Monfort A, Jutras M, Martin B, et al. New data on the transfer of untested medication into breast milk. Birth Defects Res. 2021;113:831. Abstract.

## Substance Identification

### Substance Name

Letrozole

### CAS Registry Number

112809-51-5

### Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Aromatase Inhibitors